Precision Therapeutics, Inc. Release: ChemoFx® Chemoresponse Assay Identifies Platinum-Resistance in Primary Ovarian Cancer Patients

Published: Jul 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics, a leading life-science company dedicated to the improvement of patient outcomes in personalized medicine, today announced findings that support the ChemoFx® chemoresponse assay as a tool to aid in the identification of platinum resistance in primary ovarian cancer, according to a presentation at the Annual Meeting of The Western Association of Gynecologic Oncologists (WAGO) June 26-29, in Seattle, Washington. This scientific poster was chosen for display at the WAGO conference due to the significance of the scientific discovery for treating primary ovarian cancer patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news